Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022000946 - PARP INHIBITOR CONTAINING PHTHALAZIN-1(2H)-ONE STRUCTURE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF

Publication Number WO/2022/000946
Publication Date 06.01.2022
International Application No. PCT/CN2020/130061
International Filing Date 19.11.2020
IPC
C07D 403/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
10linked by a carbon chain containing aromatic rings
C07D 405/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14containing three or more hetero rings
A61K 31/502 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
50Pyridazines; Hydrogenated pyridazines
502ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/502
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
50Pyridazines; Hydrogenated pyridazines
502ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 403/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
02containing two hetero rings
10linked by a carbon chain containing aromatic rings
C07D 405/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14containing three or more hetero rings
Applicants
  • 中国药科大学 CHINA PHARMACEUTICAL UNIVERSITY [CN]/[CN]
  • 江苏天士力帝益药业有限公司 JIANGSU TASLYDIYI PHARMACEUTICAL CO., LTD. [CN]/[CN]
Inventors
  • 朱启华 ZHU, Qihua
  • 张广霞 ZHANG, Guangxia
  • 吴尧尧 WU, Yaoyao
  • 孙进进 SUN, Jinjin
  • 张宏波 ZHANG, Hongbo
  • 徐云根 XU, Yungen
Agents
  • 南京天华专利代理有限责任公司 NANJING TIANHUA PATENT AGENT CO., LTD.
Priority Data
202010604958.729.06.2020CN
202011262555.512.11.2020CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) PARP INHIBITOR CONTAINING PHTHALAZIN-1(2H)-ONE STRUCTURE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF
(FR) INHIBITEUR DE PARP CONTENANT UNE STRUCTURE DE PHTALAZIN-1(2H)-ONE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION PHARMACEUTIQUE
(ZH) 含有酞嗪-1(2H)-酮结构的PARP抑制剂、其制法及医药用途
Abstract
(EN) The present invention discloses a PARP inhibitor containing a phthalazin-1(2H)-one structure, a preparation method therefor, and pharmaceutical use thereof. A compound as represented by formula (I) or a pharmaceutically acceptable salt thereof is provided. The present invention provides a new PARP inhibitor containing a phthalazin-1(2H)-one structure. The PARP inhibitor can be individually used as a therapeutic agent for a tumor, or can be used in combination with other anti-tumor drugs, to achieve the effects of improving the therapeutic effect of existing anti-tumor drugs and reducing the dose and toxicity.
(FR) La présente invention concerne un inhibiteur de PARP contenant une structure de phtalazin-1(2أ)-one, son procédé de préparation et son utilisation pharmaceutique. L'invention concerne un composé tel que représenté par la formule (I) ou un sel pharmaceutiquement acceptable de celui-ci. La présente invention concerne un nouvel inhibiteur de PARP contenant une structure de phtalazin-1(2H)-one. L'inhibiteur de PARP peut être utilisé en tant qu'agent thérapeutique seul pour une tumeur, ou peut être utilisé en combinaison avec d'autres médicaments antitumoraux, pour obtenir des effets d'amélioration de l'effet thérapeutique de médicaments antitumoraux existants et de réduction de la dose et de la toxicité.
(ZH) 本发明公开了含有酞嗪-1(2H)-酮结构的PARP抑制剂、其制法及医药用途。通式(I)的化合物或其药学上可接受的盐:本发明提供了一些新的含有酞嗪-1(2H)-酮结构的PARP抑制剂,可作为肿瘤的单一治疗剂,或者与其它抗肿瘤药物联用,从而达到提高现有抗肿瘤药物疗效并降低剂量和毒性的作用。
Related patent documents
Latest bibliographic data on file with the International Bureau